Mesothelioma

New Indication: Lenvatinib with Pembrolizumab in Pleural Mesothelioma

2023-11-20

  • Study

    Single-arm, single-centre, phase 2 study (PEMMELA)
    Pleural mesothelioma, who progressed after chemotherapy
    Pembrolizumab + Lenvatinib (n=38)


  • Efficacy

    ORR: 45% [17 of 38 pts]
    6 mos DCR: 47% [18 of 38 pts]
    mPFS: 5.6 mos [4.5-8.5]
    mOS: 12.8 mos [10.9-17.6]
    mDOR: 6.2 mos [2.9-10.2


  • Safety

    Hypertension (21%), anorexia (16%), ALT increased (13%), lymphopenia (13%).


    • Lancet Oncol, 24 (11), P1219-1228, NOV 2023

    Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a singlearm phase 2 study

    http://www.ncbi.nlm.nih.gov/pubmed/0

    Reviewed by Elvin Chalabiyev, MD on Nov 20, 2023